[Ed. Note: Kyle Dennis runs BiotechBreakouts.com. He is an event-based trader, who prefers low-priced and small-cap biotech stocks.
I’ll be taking a stab and building into some new positions soon. Some of the names on here will be having Earning Calls in early March, so I’m be patient with those – while others have already reported.
That makes me just want to be patient overall. I might take a small position in some of the higher priced names that have been doing well for the time being.
Just a reminder, charts and targets are updated every Monday morning!
Catalyst Swing names (1 – 4 week holds) I am watching…
Selecta Biosciences (SELB)
Catalyst Dates: Phase 2 data in early April
Buy Zone: $8.50 to $9.50
Profit Zone: $11.50 or higher
Stop Zone: $8.00 or below
Viking Therapeutics (VKTX)
Catalyst Dates: Phase 2 data for fatty liver disease due out in the 2nd quarter.
Buy Zone: $6.00 to $6.50
Profit Zone: $7.50 or higher
Stop Zone: $5.50 or below
Seattle Genetics (SGEN)
Catalyst Dates: FDA approval date of May 1
Buy Zone: $53.00 to $56.00
Profit Zone: $60.00 or higher
Stop Zone: $51.50 or below
Dova Pharmaceuticals (DOVA)
Catalyst Dates: FDA approval date of May 21
Buy Zone: $30.00 to $32.00
Profit Zone: $36.00 or higher
Stop Zone: $29.50 or below
Aimmune Therapeutics (AIMT)
Catalyst Dates: Phase 3 data at a conference March 2nd-5th (data already out, faster play)
Buy Zone: $32.00 to $33.00
Profit Zone: $35.50 or higher
Stop Zone: $31.50 or below
Rigel Pharmaceuticals (RIGL)
Catalyst Dates: FDA approval date of April 17th for immune thrombocytopenic purpura
Buy Zone: $3.50 to $3.90
Profit Zone: $4.50 or higher
Stop Zone: $3.40 or below
Clovis Oncology (CLVS)
Catalyst Dates: FDA approval date of April 6th for ovarian cancer
Buy Zone: $52.00 to $55.00
Profit Zone: $60.00 or higher
Stop Zone: $49.00 or below
Savara (SVRA)
Catalyst Dates: Phase 2 heart failure data due on March 11th
Buy Zone: $11.75 to $12.50
Profit Zone: $14.00 or higher
Stop Zone: $11.00 or below
Ultragenyx Pharmaceuticals (RARE)
Catalyst Dates: FDA approval date of April 17th for X-linked Hypophosphatemia
Buy Zone: $44.00 to $47.00
Profit Zone: $55.00 or higher
Stop Zone: $41.00 or below
Progenics (PGNX)
Catalyst Dates: FDA Approval date of April 30th
Buy Zone: $5.50 to $6.00
Profit Zone: $7.00 or higher
Stop Zone: $5.10 or below
CorMedix (CRMD)
Catalyst Dates: Phase 3 interim analysis due out in the second quarter. Likely a buy after their earnings call in March.
Buy Zone: $.30 to $.40
Profit Zone: $.70 or higher
Stop Zone: $.25 or below
EDAP Tms (EDAP)
Catalyst Dates: FDA medical device approval for prostate cancer likely late 1Q
Buy Zone: $2.40 to $2.70
Profit Zone: $3.40 or higher
Stop Zone: $2.20 or below
Nabriva Therapeutics (NBRV)
Catalyst Dates: Phase 3 antibiotic data due out “spring 2018”
Buy Zone: $5.50 to $6.00
Profit Zone: $8.00 or higher
Stop Zone: $5.20 or below
Cidara Therapeutics (CDTX)
Catalyst Dates: Phase 2 Candidemia data due in the 1Q (likely sometime in March)
Buy Zone: $6.00 to $6.50
Profit Zone: $8.40 or higher
Stop Zone: $5.75 or below
Sophiris Bio (SPHS)
Catalyst Dates: Phase 2b initial biopsy data due late First Quarter.
Buy Zone: $1.95 to $2.15
Profit Zone: $2.40 or higher
Stop Zone: $1.75 or below
